Gerrit Dispersyn - 01 Mar 2022 Form 4 Insider Report for Phio Pharmaceuticals Corp. (PHIO)

Reporting relationship: President & CEO, Director
Issuer ticker: PHIO
Reported as of: 01 Mar 2022
Net transaction value: -$7,351
SEC form: 4
Accepted by SEC: 03 Mar 2022, 18:12:51 UTC
Prior SEC filing: 16 Feb 2022
Source filing: View source filing
Reporting owner signature: Caitlin Kontulis, attorney-in-fact

Key filing fact

Gerrit Dispersyn filed Form 4 for Phio Pharmaceuticals Corp. (PHIO) on 03 Mar 2022.

Key facts

This page summarizes Gerrit Dispersyn's Form 4 filing for Phio Pharmaceuticals Corp. (PHIO).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 03 Mar 2022, 18:12.

Change

Previous filing in this sequence was filed on 16 Feb 2022.
Current net transaction value: -$7,351.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PHIO transaction

Common stock, $0.0001 par value

Tax liability

Transaction value: $7,351
Shares: -8,954
Change %: -4%
Price: $0.8210
Shares after: 212,327
Date: 01 Mar 2022
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting of restricted stock units. No shares were sold.

Footnote F2

Includes shares of common stock underlying unvested restricted stock units.